Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Type I interferon response impairs differentiation potential of pluripotent stem cells.

Eggenberger J, Blanco-Melo D, Panis M, Brennand KJ, tenOever BR.

Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1384-1393. doi: 10.1073/pnas.1812449116. Epub 2019 Jan 3.

2.

Homologous recombination is an intrinsic defense against antiviral RNA interference.

Aguado LC, Jordan TX, Hsieh E, Blanco-Melo D, Heard J, Panis M, Vignuzzi M, tenOever BR.

Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):E9211-E9219. doi: 10.1073/pnas.1810229115. Epub 2018 Sep 12.

3.

miRNA-mediated targeting of human cytomegalovirus reveals biological host and viral targets of IE2.

Møller R, Schwarz TM, Noriega VM, Panis M, Sachs D, Tortorella D, tenOever BR.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1069-1074. doi: 10.1073/pnas.1719036115. Epub 2018 Jan 16.

4.

RNase III Nucleases and the Evolution of Antiviral Systems.

Aguado LC, tenOever BR.

Bioessays. 2018 Feb;40(2). doi: 10.1002/bies.201700173. Epub 2017 Dec 21. Review.

PMID:
29266287
5.

Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.

Wohlbold TJ, Podolsky KA, Chromikova V, Kirkpatrick E, Falconieri V, Meade P, Amanat F, Tan J, tenOever BR, Tan GS, Subramaniam S, Palese P, Krammer F.

Nat Microbiol. 2017 Oct;2(10):1415-1424. doi: 10.1038/s41564-017-0011-8. Epub 2017 Aug 21.

6.

RNase III nucleases from diverse kingdoms serve as antiviral effectors.

Aguado LC, Schmid S, May J, Sabin LR, Panis M, Blanco-Melo D, Shim JV, Sachs D, Cherry S, Simon AE, Levraud JP, tenOever BR.

Nature. 2017 Jul 6;547(7661):114-117. doi: 10.1038/nature22990. Epub 2017 Jun 28.

7.

Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.

Duehr J, Wohlbold TJ, Oestereich L, Chromikova V, Amanat F, Rajendran M, Gomez-Medina S, Mena I, tenOever BR, García-Sastre A, Basler CF, Munoz-Fontela C, Krammer F.

J Virol. 2017 Jul 27;91(16). pii: e00652-17. doi: 10.1128/JVI.00652-17. Print 2017 Aug 15.

8.

Questioning antiviral RNAi in mammals.

tenOever BR.

Nat Microbiol. 2017 Apr 25;2:17052. doi: 10.1038/nmicrobiol.2017.52. No abstract available.

PMID:
28440277
9.

Efficient and Robust Paramyxoviridae Reverse Genetics Systems.

Beaty SM, Park A, Won ST, Hong P, Lyons M, Vigant F, Freiberg AN, tenOever BR, Duprex WP, Lee B.

mSphere. 2017 Mar 29;2(2). pii: e00376-16. doi: 10.1128/mSphere.00376-16. eCollection 2017 Mar-Apr.

10.

SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology.

Morales L, Oliveros JC, Fernandez-Delgado R, tenOever BR, Enjuanes L, Sola I.

Cell Host Microbe. 2017 Mar 8;21(3):344-355. doi: 10.1016/j.chom.2017.01.015. Epub 2017 Feb 16.

11.

DAI Senses Influenza A Virus Genomic RNA and Activates RIPK3-Dependent Cell Death.

Thapa RJ, Ingram JP, Ragan KB, Nogusa S, Boyd DF, Benitez AA, Sridharan H, Kosoff R, Shubina M, Landsteiner VJ, Andrake M, Vogel P, Sigal LJ, tenOever BR, Thomas PG, Upton JW, Balachandran S.

Cell Host Microbe. 2016 Nov 9;20(5):674-681. doi: 10.1016/j.chom.2016.09.014. Epub 2016 Oct 13.

12.

The Evolution of Antiviral Defense Systems.

tenOever BR.

Cell Host Microbe. 2016 Feb 10;19(2):142-9. doi: 10.1016/j.chom.2016.01.006. Review.

13.

microRNA Function Is Limited to Cytokine Control in the Acute Response to Virus Infection.

Aguado LC, Schmid S, Sachs D, Shim JV, Lim JK, tenOever BR.

Cell Host Microbe. 2015 Dec 9;18(6):714-22. doi: 10.1016/j.chom.2015.11.003.

14.

Engineered Mammalian RNAi Can Elicit Antiviral Protection that Negates the Requirement for the Interferon Response.

Benitez AA, Spanko LA, Bouhaddou M, Sachs D, tenOever BR.

Cell Rep. 2015 Nov 17;13(7):1456-1466. doi: 10.1016/j.celrep.2015.10.020. Epub 2015 Nov 5.

15.

In Vivo RNAi Screening Identifies MDA5 as a Significant Contributor to the Cellular Defense against Influenza A Virus.

Benitez AA, Panis M, Xue J, Varble A, Shim JV, Frick AL, López CB, Sachs D, tenOever BR.

Cell Rep. 2015 Jun 23;11(11):1714-26. doi: 10.1016/j.celrep.2015.05.032. Epub 2015 Jun 11.

16.

Influenza A virus transmission bottlenecks are defined by infection route and recipient host.

Varble A, Albrecht RA, Backes S, Crumiller M, Bouvier NM, Sachs D, García-Sastre A, tenOever BR.

Cell Host Microbe. 2014 Nov 12;16(5):691-700. doi: 10.1016/j.chom.2014.09.020. Epub 2014 Oct 23.

17.

Response to Voinnet et al.

tenOever BR.

Cell Rep. 2014 Nov 6;9(3):798-9. doi: 10.1016/j.celrep.2014.10.030. No abstract available.

18.

The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon.

Laurent-Rolle M, Morrison J, Rajsbaum R, Macleod JML, Pisanelli G, Pham A, Ayllon J, Miorin L, Martinez C, tenOever BR, García-Sastre A.

Cell Host Microbe. 2014 Sep 10;16(3):314-327. doi: 10.1016/j.chom.2014.07.015.

19.

Long-term survival of influenza virus infected club cells drives immunopathology.

Heaton NS, Langlois RA, Sachs D, Lim JK, Palese P, tenOever BR.

J Exp Med. 2014 Aug 25;211(9):1707-14. doi: 10.1084/jem.20140488. Epub 2014 Aug 18.

20.

Stem-loop recognition by DDX17 facilitates miRNA processing and antiviral defense.

Moy RH, Cole BS, Yasunaga A, Gold B, Shankarling G, Varble A, Molleston JM, tenOever BR, Lynch KW, Cherry S.

Cell. 2014 Aug 14;158(4):764-777. doi: 10.1016/j.cell.2014.06.023.

21.

The Mammalian response to virus infection is independent of small RNA silencing.

Backes S, Langlois RA, Schmid S, Varble A, Shim JV, Sachs D, tenOever BR.

Cell Rep. 2014 Jul 10;8(1):114-25. doi: 10.1016/j.celrep.2014.05.038. Epub 2014 Jun 19.

22.

Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKε kinase-mediated antiviral response.

Rajsbaum R, Versteeg GA, Schmid S, Maestre AM, Belicha-Villanueva A, Martínez-Romero C, Patel JR, Morrison J, Pisanelli G, Miorin L, Laurent-Rolle M, Moulton HM, Stein DA, Fernandez-Sesma A, tenOever BR, García-Sastre A.

Immunity. 2014 Jun 19;40(6):880-95. doi: 10.1016/j.immuni.2014.04.018. Epub 2014 May 29.

23.

Drosha as an interferon-independent antiviral factor.

Shapiro JS, Schmid S, Aguado LC, Sabin LR, Yasunaga A, Shim JV, Sachs D, Cherry S, tenOever BR.

Proc Natl Acad Sci U S A. 2014 May 13;111(19):7108-13. doi: 10.1073/pnas.1319635111. Epub 2014 Apr 28.

24.

A versatile RNA vector for delivery of coding and noncoding RNAs.

Schmid S, Zony LC, tenOever BR.

J Virol. 2014 Feb;88(4):2333-6. doi: 10.1128/JVI.03267-13. Epub 2013 Dec 4.

25.

Mitogen-activated protein kinase-mediated licensing of interferon regulatory factor 3/7 reinforces the cell response to virus.

Schmid S, Sachs D, tenOever BR.

J Biol Chem. 2014 Jan 3;289(1):299-311. doi: 10.1074/jbc.M113.519934. Epub 2013 Nov 25.

26.

Is RNA interference a physiologically relevant innate antiviral immune response in mammals?

Cullen BR, Cherry S, tenOever BR.

Cell Host Microbe. 2013 Oct 16;14(4):374-8. doi: 10.1016/j.chom.2013.09.011. Review.

27.

An in vivo RNAi screening approach to identify host determinants of virus replication.

Varble A, Benitez AA, Schmid S, Sachs D, Shim JV, Rodriguez-Barrueco R, Panis M, Crumiller M, Silva JM, Sachidanandam R, tenOever BR.

Cell Host Microbe. 2013 Sep 11;14(3):346-56. doi: 10.1016/j.chom.2013.08.007.

28.

MicroRNA-based strategy to mitigate the risk of gain-of-function influenza studies.

Langlois RA, Albrecht RA, Kimble B, Sutton T, Shapiro JS, Finch C, Angel M, Chua MA, Gonzalez-Reiche AS, Xu K, Perez D, García-Sastre A, tenOever BR.

Nat Biotechnol. 2013 Sep;31(9):844-847. doi: 10.1038/nbt.2666. Epub 2013 Aug 11.

29.

RNA viruses and the host microRNA machinery.

tenOever BR.

Nat Rev Microbiol. 2013 Mar;11(3):169-80. doi: 10.1038/nrmicro2971. Review.

PMID:
23411862
30.

Influenza A virus utilizes suboptimal splicing to coordinate the timing of infection.

Chua MA, Schmid S, Perez JT, Langlois RA, Tenoever BR.

Cell Rep. 2013 Jan 31;3(1):23-9. doi: 10.1016/j.celrep.2012.12.010. Epub 2013 Jan 17.

31.

A small-RNA enhancer of viral polymerase activity.

Perez JT, Zlatev I, Aggarwal S, Subramanian S, Sachidanandam R, Kim B, Manoharan M, tenOever BR.

J Virol. 2012 Dec;86(24):13475-85. doi: 10.1128/JVI.02295-12. Epub 2012 Oct 3.

32.

Degradation of host microRNAs by poxvirus poly(A) polymerase reveals terminal RNA methylation as a protective antiviral mechanism.

Backes S, Shapiro JS, Sabin LR, Pham AM, Reyes I, Moss B, Cherry S, tenOever BR.

Cell Host Microbe. 2012 Aug 16;12(2):200-10. doi: 10.1016/j.chom.2012.05.019.

33.

Hematopoietic-specific targeting of influenza A virus reveals replication requirements for induction of antiviral immune responses.

Langlois RA, Varble A, Chua MA, García-Sastre A, tenOever BR.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12117-22. doi: 10.1073/pnas.1206039109. Epub 2012 Jul 9.

34.

Evidence for a cytoplasmic microprocessor of pri-miRNAs.

Shapiro JS, Langlois RA, Pham AM, Tenoever BR.

RNA. 2012 Jul;18(7):1338-46. doi: 10.1261/rna.032268.112. Epub 2012 May 25.

35.

Replication in cells of hematopoietic origin is necessary for Dengue virus dissemination.

Pham AM, Langlois RA, TenOever BR.

PLoS Pathog. 2012 Jan;8(1):e1002465. doi: 10.1371/journal.ppat.1002465. Epub 2012 Jan 5.

36.

IκB kinase epsilon (IKK(epsilon)) regulates the balance between type I and type II interferon responses.

Ng SL, Friedman BA, Schmid S, Gertz J, Myers RM, Tenoever BR, Maniatis T.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21170-5. doi: 10.1073/pnas.1119137109. Epub 2011 Dec 14.

37.

In vivo delivery of cytoplasmic RNA virus-derived miRNAs.

Langlois RA, Shapiro JS, Pham AM, tenOever BR.

Mol Ther. 2012 Feb;20(2):367-75. doi: 10.1038/mt.2011.244. Epub 2011 Nov 15.

38.

Transcription factor redundancy ensures induction of the antiviral state.

Schmid S, Mordstein M, Kochs G, García-Sastre A, Tenoever BR.

J Biol Chem. 2010 Dec 31;285(53):42013-22. doi: 10.1074/jbc.M110.165936. Epub 2010 Oct 13.

39.

Noncanonical cytoplasmic processing of viral microRNAs.

Shapiro JS, Varble A, Pham AM, Tenoever BR.

RNA. 2010 Nov;16(11):2068-74. doi: 10.1261/rna.2303610. Epub 2010 Sep 14.

40.

Engineered RNA viral synthesis of microRNAs.

Varble A, Chua MA, Perez JT, Manicassamy B, García-Sastre A, tenOever BR.

Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11519-24. doi: 10.1073/pnas.1003115107. Epub 2010 Jun 7.

41.

Influenza A virus-generated small RNAs regulate the switch from transcription to replication.

Perez JT, Varble A, Sachidanandam R, Zlatev I, Manoharan M, García-Sastre A, tenOever BR.

Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11525-30. doi: 10.1073/pnas.1001984107. Epub 2010 Jun 1.

42.

Antiviral response dictated by choreographed cascade of transcription factors.

Zaslavsky E, Hershberg U, Seto J, Pham AM, Marquez S, Duke JL, Wetmur JG, Tenoever BR, Sealfon SC, Kleinstein SH.

J Immunol. 2010 Mar 15;184(6):2908-17. doi: 10.4049/jimmunol.0903453. Epub 2010 Feb 17.

43.

The IKK Kinases: Operators of Antiviral Signaling.

Pham AM, Tenoever BR.

Viruses. 2010 Jan;2(1):55-72. doi: 10.3390/v2010055. Epub 2010 Jan 8.

44.

MicroRNA-mediated species-specific attenuation of influenza A virus.

Perez JT, Pham AM, Lorini MH, Chua MA, Steel J, tenOever BR.

Nat Biotechnol. 2009 Jun;27(6):572-6. doi: 10.1038/nbt.1542. Epub 2009 May 31.

PMID:
19483680
45.

Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity.

Tenoever BR, Ng SL, Chua MA, McWhirter SM, García-Sastre A, Maniatis T.

Science. 2007 Mar 2;315(5816):1274-8.

46.

Parallel pathways of virus recognition.

Tenoever BR, Maniatis T.

Immunity. 2006 May;24(5):510-2. Review.

47.

Connecting mitochondria and innate immunity.

McWhirter SM, Tenoever BR, Maniatis T.

Cell. 2005 Sep 9;122(5):645-7. Review.

48.

Regulation of arginase II by interferon regulatory factor 3 and the involvement of polyamines in the antiviral response.

Grandvaux N, Gaboriau F, Harris J, tenOever BR, Lin R, Hiscott J.

FEBS J. 2005 Jun;272(12):3120-31.

49.

Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity.

tenOever BR, Sharma S, Zou W, Sun Q, Grandvaux N, Julkunen I, Hemmi H, Yamamoto M, Akira S, Yeh WC, Lin R, Hiscott J.

J Virol. 2004 Oct;78(19):10636-49.

50.

A requirement for NF-kappaB induction in the production of replication-competent HHV-8 virions.

Sgarbanti M, Arguello M, tenOever BR, Battistini A, Lin R, Hiscott J.

Oncogene. 2004 Jul 29;23(34):5770-80.

PMID:
15235582

Supplemental Content

Loading ...
Support Center